`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Case IPR2017-01053
`Patent 8,268,299
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner
`
`v.
`
`ALCON RESEARCH, LTD.,
`Patent Owner
`
`
`Case IPR2017-01053
`Patent 8,268,299
`
`
`ALCON RESEARCH, LTD.’S MOTION TO SEAL AND MOTION FOR
`ENTRY OF PROPOSED PROTECTIVE ORDER
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2017-01053
`
`Patent 8,268,299
`
`Pursuant to 37 C.F.R. §§ 42.14 and 42.54, Patent Owner Alcon Research,
`
`Ltd. (“Alcon”) hereby respectfully moves to seal confidential laboratory notebooks
`
`and adjunctive data (Exhibits 2008–2022), portions of the Declaration of Dr. Henry
`
`Grabowski, Ph.D. (Exhibit 2029), and certain exhibits on which Dr. Grabowski
`
`relied in forming his opinions (Exhibits 2040–2058). In support of this Motion,
`
`Alcon is also submitting a proposed protective order (Exhibit 2140), which is the
`
`Default Standing Protective Order. See 37 C.F.R. § 42.54(a).
`
`A. Motion to Seal
`The standard for granting a motion to seal is “for good cause.” 37 C.F.R.
`
`§ 42.54; Decision – Revised Motion to Seal, Garmin Int’l, Inc. v. Cuozzo Speed
`
`Techs. LLC, Case IPR2012-00001 (JL), at 4 (Apr. 5, 2013) (hereinafter Garmin
`
`Decision). Good cause exists for sealing these exhibits.
`
`Laboratory notebooks and adjunctive data
`
`1.
`Exhibits 2008–2022 are excerpts of confidential laboratory notebooks and
`
`adjunctive data used by Alcon employees to record their research and development
`
`work. These documents are being submitted in support of affidavits filed pursuant
`
`to 37 C.F.R. § 42.61 describing how certain data in the specifications of Alcon
`
`patents were generated. Although the data on which Alcon relies in this
`
`proceeding are disclosed in public patent specifications, the documents Alcon
`
`proposes to seal also disclose internal Alcon laboratory methods and practices and
`
`
`
`2
`
`
`
`Case IPR2017-01053
`
`
`Patent 8,268,299
`
`
`additional, unpublished testing data. Public disclosure of these confidential,
`
`internal documents reflecting Alcon’s research and development work has the
`
`potential to cause Alcon competitive harm.
`
`Because the data on which Alcon relies in this proceeding are already in the
`
`public record, the public’s interest in having access to these documents in order to
`
`“maintain a complete and understandable file history” is minimal. Garmin
`
`Decision at 8 (balancing need for confidentiality against public’s interest).
`
`Moreover, pursuant to 37 C.F.R. § 42.61, these documents are being submitted in
`
`conjunction with the declarations of Bhagwati Kabra, Ph.D., and Stephen Shannon,
`
`MBA, Ph.D. Dr. Kabra’s and Dr. Shannon’s declarations explain the testing data
`
`in the patent specification, explain in general the significance of the laboratory
`
`notebooks and adjunctive data, and are not being filed under seal. Accordingly, a
`
`“complete and understandable file history” will be available to the public even if
`
`these exhibits are sealed.
`
`2.
`
`Summaries of IMS Health/IQVIA and Encuity Research
`Data
`
`Exhibits 2040–2058 summarize data provided to Alcon by IMS
`
`Health/IQVIA and Encuity Research. These exhibits contain data on sales, units,
`
`prescriptions, and promotional spending for a number of pharmaceutical products.
`
`These data were provided by IMS Health/IQVIA and Encuity Research to Alcon or
`
`to counsel for Alcon pursuant to agreements to keep the data confidential. It is
`
`
`
`3
`
`
`
`Case IPR2017-01053
`
`
`Patent 8,268,299
`
`
`undersigned counsel’s understanding that IMS Health/IQVIA and Encuity
`
`Research charge customers for these data, that they do not make their data
`
`generally available to the public, and that they would be harmed by the public
`
`disclosure of these data without a confidentiality agreement.
`
`The public’s interest in having access to these exhibits is minimal. See
`
`Garmin Decision at 8. These exhibits are being provided in support of the
`
`declaration of Dr. Henry Grabowski, Ph.D. In conjunction with this motion, Alcon
`
`is submitting a non-confidential, redacted version of Dr. Grabowski’s declaration.
`
`The substance of Dr. Grabowski’s opinions can be fully ascertained from the
`
`redacted declaration; the only information not reflected in the redacted declaration
`
`is data from IMS Health/IQVIA and Encuity Research and Dr. Grabowski’s
`
`specific calculations based on that data. Moreover, interested members of the
`
`public can obtain the data in question directly from IMS Health/IQVIA and
`
`Encuity Research (presumably for a fee).
`
`Dr. Grabowski’s Declaration
`
`3.
`Exhibit AL 2029 is the declaration of Dr. Henry Grabowski, Ph.D. This
`
`exhibit discloses data (and calculations derived therefrom) obtained from IMS
`
`Health/IQVIA and Encuity Research. As explained above, good cause exists to
`
`seal these data, see supra Part A.2, and for the same reasons, good cause exists to
`
`
`
`4
`
`
`
`Case IPR2017-01053
`
`
`Patent 8,268,299
`
`
`seal the portions of Dr. Grabowski’s declaration which disclose these data or
`
`calculations derived therefrom.
`
`Proposed Protective Order
`
`B.
`Pursuant to 37 C.F.R. § 42.54, Alcon is submitting a proposed protective
`
`order, attached hereto as Exhibit 2140, which is the Default Standing Protective
`
`Order. Alcon requests that the proposed protective order be entered and that its
`
`terms govern the confidentiality of the exhibits which are the subject of this
`
`motion.
`
`C. Certification of Conference with Opposing Party Pursuant to 37
`C.F.R. § 42.54
`
`Alcon certifies that it wrote to Argentum’s counsel on December 22, 2017
`
`regarding Argentum’s consent to the entry of the proposed protective order, but did
`
`not receive a response before filing this motion.
`
`D. Conclusion
`For the foregoing reasons, Alcon respectfully requests that its motion to seal
`
`be granted and that the PTAB enter the proposed protective order.
`
`
`
`Dated: December 22, 2017
`
`Respectfully submitted,
`
`/David M. Krinsky/
`David M. Krinsky
`Reg. No. 72,339
`Lead Counsel for
`Patent Owner
`
`5
`
`
`
`
`
`
`
`
`
`
`Case IPR2017-01053
`
`Patent 8,268,299
`
`Williams & Connolly LLP
`725 Twelfth Street NW
`Washington, D.C. 20005
`202-434-5338 (Telephone)
`202-434-5029 (Facsimile)
`dkrinsky@wc.com
`
`
`
`6
`
`
`
`
`
`
`Case IPR2017-01053
`
`Patent 8,268,299
`
`CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))
`
`The undersigned hereby certifies that the foregoing “ALCON RESEARCH,
`
`LTD.’S MOTION TO SEAL AND MOTION FOR ENTRY OF PROPOSED
`
`PROTECTIVE ORDER” was served on December 22, 2017, via electronic mail
`
`upon the following attorneys of record for the Petitioner:
`
`Michael R. Houston
`Joseph P. Meara
`James P. McParland
`FOLEY & LARDNER LLP
`mhouston@foley.com
`jmeara-pgp@foley.com
`jmcparland@foley.com
`ARG-travatanZ@foley.com
`
`Tyler C. Liu
`ARGENTUM PHARMACEUTICALS LLC
`tliu@agpharm.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/David M. Krinsky/
`David M. Krinsky
`Reg. No. 72,339
`Lead Counsel for Patent Owner
`
`
`
`
`
`Dated: December 22, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`7
`
`